Saturday, June 25, 2022

Moderna eyes fed authorization of Covid-19 vaccine in children under 6

New Hanover County received about 4,800 doses of the Moderna Covid-19 vaccine a few days before Christmas. Over 1,300 doses have been administered. (Courtesy New Hanover County)

Moderna has completed a second-phase study for using its Covid-19 vaccine in children aged six months to under 6 years, it noted in a press release. In coming weeks, it’s planning to apply for federal authorization from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

The study noted it administered two 25 microgram doses of mRNA-1273 to children six months to under 6 years. The vaccine amount equates to 25% of the mRNA-1273 robust neutralizing antibody titers given to adults.

“Given the need for a vaccine against COVID-19 in infants and young children, we are working with the U.S. FDA and regulators globally to submit these data as soon as possible,” Moderna CEO Stéphane Bancel said in the statement.

A study was conducted during the omicron wave, with micro doses administered 28 days apart. Nearly 11,700 pediatric participants have been enrolled in the company’s study in the U.S. and Canada for all youth up to 18. Approximately 4,200 of the participants are two to under 6 years old, and 2,500 are six months to under 2 years of age. Around 6,700 participants are six months to under 6 years old. 

Only 17% of six months to under 6-year-olds reported adverse reactions such as fever; those 2 to under 6 years old reported 14.6% experienced adverse events. There were no extreme reactions — death, myocarditis, pericarditis, or multisystem inflammatory syndrome — reported in the study.  

Efficacy in children six months to 2 years was 43.7%, and in children 2 to under 6 years, 37.5%. No severe Covid-19 cases were reported in either age group. 

Moderna is preparing to evaluate boosters of mRNA-1273, its booster candidate mRNA-1273.214, including the omicron variant booster and mRNA-1273. The boosters are being evaluated for pediatric patients six months to under 6 years, 6 to under 12 years, and adolescents.

Study participants will be monitored for 12 months following their second dose to assess long-term safety and health status. All data will be overseen by an independent safety monitoring committee.


Have tips or comments? Email info@portcitydaily.com

Shea Carver
Shea Carver is the editor in chief at Port City Daily. A UNCW alumna, Shea worked in the print media business in Wilmington for 22 years before joining the PCD team in October 2020. She specializes in arts coverage — music, film, literature, theatre — the dining scene, and can often be tapped on where to go, what to do and who to see in Wilmington. When she isn’t hanging with her pup, Shadow Wolf, tending the garden or spinning vinyl, she’s attending concerts and live theater.

Related Articles